Proprietary Markings. To the extent commercially feasible, Company will ▇▇▇▇ all material forms of Licensed Products or packaging pertaining thereto made and sold by Company in the United States with patent marking conforming to 35 U.S.C. §287(a), as amended from time to time. All Licensed Product(s) shipped to or sold in other countries will be marked in such a manner as to provide notice to potential infringers pursuant to the patent law and practice of the country of manufacture or sale.
Appears in 5 contracts
Sources: License and Exclusive Option Agreement (Icosavax, Inc.), License and Exclusive Option Agreement (Icosavax, Inc.), Exclusive Start Up License Agreement (Sana Biotechnology, Inc.)
Proprietary Markings. To the extent commercially feasible, Company will ▇▇▇▇ mark all material forms of Licensed Products or packaging pertaining thereto made and sold by Company in the United States with patent marking conforming to 35 U.S.C. §287(a), as amended from time to time. All Licensed Product(s) shipped to or sold in other countries will be marked in such a manner as to provide notice to potential infringers pursuant to the patent law and practice of the country of manufacture or sale.
Appears in 5 contracts
Sources: Exclusive License Agreement (Promicell, Inc.), Exclusive License Agreement (Promicell, Inc.), Exclusive License Agreement (Promicell, Inc.)
Proprietary Markings. To the extent commercially feasible, Company will ▇m▇▇▇ all material forms of Licensed Products or packaging pertaining thereto made and sold by Company in the United States with patent marking conforming to 35 U.S.C. §287(a), as amended from time to time. All Licensed Product(s) shipped to or sold in other countries will be marked in such a manner as to provide notice to potential infringers pursuant to the patent law and practice of the country of manufacture or sale.
Appears in 1 contract
Sources: Exclusive License Agreement (Akoya Biosciences, Inc.)